In its second-quarter 13F filing, specialist investment firm Baker Bros. Advisors revealed a portfolio valued at $19.96 billion. As a prominent and highly focused biotechnology investor, the firm's moves are closely watched for signs of conviction in the life sciences sector. The filing for the period ending June 30, 2026, shows that top holdings like Incyte (INCY) and Olema Oncology (ONC) continue to anchor the portfolio, representing 17.48% and 12.57% of the fund's value, respectively. The firm is known for its concentrated, long-term positions in biotech companies.
The most significant change was a substantial increase in its holding of Revolution Medicines (RVMD), a company developing targeted therapies for cancer. Baker Bros. increased its share count by over 20%, making RVMD the third-largest position and nearly doubling its portfolio weight from 5.34% to 10.74%. Another high-conviction addition was made to Insmed (INSM), a biopharmaceutical company focused on serious and rare diseases, with shares increasing by nearly 1.4 million.
Conversely, the firm exited several positions entirely, signaling a strategic reallocation of capital. Baker Bros. liquidated its holdings in Abivax (ABVX), Syros Pharmaceuticals (SYRE), and a convertible note for Celldex Therapeutics (CELC). It also moderately reduced its stake in Edgewise Therapeutics (EWTX). These high-signal exits, combined with the major increase in its RVMD stake, reflect an active and concentrated management style.